Marten Fryknas

Uppsala, C, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus.

Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus.

Journal: Scientific reports
Published: December 02, 2024

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models.

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models.

Journal: SLAS technology
Published: October 15, 2024

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model.

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model.

Journal: Oncology reports
Published: September 04, 2024

OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids.

OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids.

Journal: Scientific reports
Published: January 25, 2024

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment.

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment.

Journal: BMC pharmacology & toxicology
Published: July 05, 2023

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death.

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death.

Journal: BMC cancer
Published: November 07, 2022

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients.

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients.

Journal: Anti-cancer drugs
Published: September 06, 2022

Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma.

Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma.

Journal: Scientific reports
Published: April 08, 2022

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model.

Journal: Scientific reports
Published: February 25, 2022

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma.

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma.

Journal: Scientific reports
Published: December 16, 2021

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells.

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells.

Journal: Oncology letters
Published: May 24, 2021

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Journal: Bone reports
Published: April 22, 2021
Showing 1-12 of 51

Last Updated: 09/26/2026